Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography

Annals of Nuclear Medicine

Volumn 17, Issue 3, 2003, Pages 205-211

  Ishiwata, Kiichi ^a   Wang, Wei Fang ^a   Kimura, Yuichi ^a   Kawamura, Kazunori ^a   Ishii, Kenji ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Adenosine A2A receptor; Central nervous system; Positron emission tomography; 11C TMSX

Indexed keywords

8 (3,4,5 TRIMETHOXYSTYRYL) 1,3,7 TRIMETHYLXANTHINE; ADENOSINE A2A RECEPTOR; CARBON 11; RADIOLIGAND; THEOPHYLLINE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; KF18446; RADIOPHARMACEUTICAL AGENT; XANTHINE DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MAPPING; CORPUS STRIATUM; DRUG UPTAKE; FEMALE; MALE; MOUSE; MUTAGENICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RAT; TISSUE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DRUG SCREENING; DRUG STABILITY; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MUTAGEN TESTING; SCINTISCANNING; TOXICITY TESTING; WHOLE BODY COUNTING;

ACUTE TOXICITY TESTS; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; METABOLIC CLEARANCE RATE; MICE; MUTAGENICITY TESTS; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A2A; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING; XANTHINES;

EID: 0038268673     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02990023     Document Type: Article

References (33)

1. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143-156.
2. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 375-381.
3. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Ann Rev Neurosci 2001; 24: 31-55.
4. 3H]adenosine. Eur J Pharmacol 1981; 73: 109-110.
5. 3H]cyclohexyladenosine. J Neurosci 1982; 2: 1230-1241.
6. Fastbom J, Pazos A, Palacios JM. The distribution of adenosine A2A receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987; 22: 813-826.
7. Fastbom J, Pazos A, Probst A, Palacios JM. Adenosine A2A receptors in the human brain: a quantitative autoradiographic study. Neuroscience 1987; 22: 827-839.
8. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997; 27: 322-335.
9. 3H]-CGS21680 as a ligand. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 85-89.
10. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 1995; 34: 393-403.
11. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, et al. D1 and D2 dopamine receptor-regulated gene expression of strionigral and striopallidal neurons. Science 1990; 250: 1429-1432.
12. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991; 57: 1062-1067.
13. Pollack AE, Harrison MB, Wooten GF, Fink JS. Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res 1993; 631: 161-166.
14. 2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Mol Brain Res 1994; 22: 204-210.
15. 2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001; 65: 1447-1457.
16. Tissingh G, Booij J, Winogrodzka A, van Royen EA, Wolters EC. IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. J Neural Transm 1997; 50 (Suppl): 1-7.
17. Stoessl AJ, Ruth TJ. Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Curr Opin Neurol 1998; 11: 327-333.
18. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin 2001; 31: 321-340.
19. 2A antagonist. Appl Radiat Isot 1996; 47: 507-511.
20. 2a receptor ligand. J Nucl Med 1998; 39: 498-503.
21. 2A). Drug Develop Res 1998; 45: 312-323.
22. 2a receptor ligand. J Nucl Med 2000;41;345-354.
23. 11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann Nucl Med 2000; 14: 81-89.
24. 2a receptor in the central nervous system. Ann Nucl Med 2000; 14: 247-253.
25. 2a receptors with positron emission tomography. Nucl Med Biol 2000; 27: 541-546.
26. 11C]KF18446 PET in the rat brain following quinolinic acid lesion: comparison with the dopamine receptor imaging. Ann Nucl Med 2002; 16: 467-475.
27. 2A receptors with PET as a new diagnostic tool for neurological disorders. Drugs Fut 2002; 27: 569-576.
28. 2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem 1993; 36: 3731-3733.
29. 2 antagonists. J Med Chem 1992; 35: 2342-2345.
30. 11C]semotiadil, a benzothiazine calcium antagonist. Appl Radiat Isot 1994; 45: 439-443.
31. 18F]fluoro-D,L-phenylalanine: A target compound for PET and boron neutron capture therapy. Appl Radiat Isot 1991; 142: 325-328.
32. 18F-labeled radiopharmaceuticals. J Radiat Res 1991; 32: 243-261.
33. 11C]KF17837. Ann Nucl Med 1997; 11: 219-225.